Boehringer Ingelheim and Eli Lilly and Co. are changing the operational and financial structure of their diabetes alliance in certain countries in an effort to enhance efficiencies and enable greater focus on product launches. Under the revised agreement, effective January 1, 2015, 17 countries representing more than 90% of the alliance’s anticipated market, will continue their co-promotion work, and in all other countries, the companies will exclusively commercialize their respective mole...